Navigation Links
What's next for gene therapy? Plastic

Gene therapy depends upon foreign DNA, even viruses, to deliver genes, therapeutic proteins, or medicine to cells within the body. Many scientists are looking for better chaperones across the cell membrane. Virginia Tech researchers think polymer molecules can be created to do the job.

The research will be presented at the 232nd national meeting of the American Chemical Society in San Francisco September 10-14, 2006.

"We are applying our fundamental knowledge in polymer science to gene transfer agents," said Tim Long, professor of chemistry in the College of Science at Virginia Tech. "We are trying to understand how the structure of the chaperone impacts the efficiency of its ability to transfer DNA across the cell membrane."

Entire texts have been devoted to the subject, Long said. "But the researchers are usually biologists. Polymer scientists can bring a unique perspective that I think will lead to new advances."

Long's graduate student, John M. Layman of Richmond, Va., will share information regarding star-shaped, or highly-branched, molecules, which are extremely effective at transfection. Long's group has demonstrated that the topology of these particular polymers can be changed. "We can control the molecular shape and number of functional end groups," said Long. "We think that topology is important because it can influence the strength of the interaction with DNA and permit efficient release of the DNA for protein synthesis."

Layman will deliver the talk, "Influence of macromolecular architecture on nucleic acid transfection (POLY 611)," at 4 p.m., Wednesday, Sept. 13, in the Marriott Salon 14/15 as part of the International Biorelated Polymers Symposium. Authors are Layman, Anjali A. Hirani of the Virginia Tech-Wake Forest School of Biomedical Engineering (VT-WF SBES), Joseph M. Pickel and Phillip F. Britt of the Oak Ridge National Laboratory Chemical Sciences Division, Yong Woo Lee at VT-WF SBES, and Long.

"The paper defines a new paradigm for research," said Long. Layman, whose bachelor of science degree is from Virginia Commonwealth University in chemical engineering, "typifies the way we are going to educate students in the future," Long said. "He is an engineer working in chemistry on gene therapy. He collaborates with researchers in the Virginia Tech-Wake Forest School of Biomedical Engineering and Oak Ridge National Laboratory.
'"/>

Source:Virginia Tech


Related biology news :

1. Whats really making you sick? Plant pathologists offer the science behind Sick Building Syndrome
2. Whats shaped like a pear and has 2 genomes? Check the pond
3. Whats nature worth? New computer models tell all
4. Whats in the water? Estrogenic activity documented in fish caught in Pittsburghs rivers

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/1/2016)... YORK , June 1, 2016 ... Technology in Election Administration and Criminal Identification to Boost ... to a recently released TechSci Research report, " Global ... By Region, Competition Forecast and Opportunities, 2011 - 2021", ... 24.8 billion by 2021, on account of growing security ...
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com , ... published the overview results from the Q1 wave of ... recent wave was consumers, receptivity to a program where ... with a health insurance company. "We were ... share," says Michael LaColla , CEO of Troubadour ...
(Date:4/28/2016)... GOTHENBURG, Sweden , April 28, 2016 ... 1,491.2 M (139.9), up 966% compared with the first quarter of ... Operating profit totaled SEK 589.1 M (loss: 18.8) and the operating ... SEK 7.12 (loss: 0.32) Cash flow from operations was ... , The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Houston ... with the Cy-Fair Sports Association to serve as ... the agreement, Houston Methodist Willowbrook will provide sponsorship ... and connectivity with association coaches, volunteers, athletes and ... with the Cy-Fair Sports Association and to bring ...
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... the Pennsylvania Convention Center and will showcase its product’s latest features from June ... be presenting a scientific poster on Disrupting Clinical Trials in The Cloud during ...
Breaking Biology Technology: